Drug Combination Details
| General Information of the Combination (ID: C37427) | |||||
|---|---|---|---|---|---|
| Name | Tretinoin NP Info | + | Daratumumab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | NOTCH1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| OCI-AML-3 | CVCL_1844 | Adult acute myeloid leukemia | Homo sapiens | |||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| In-vivo Model | For the leukemic model, 3.0 * 105 spleen cells from MV4-11-engrafted mice were injected intravenously into 75 NSG mice. | |||||
| Experimental
Result(s) |
The combination of ATRA plus DARA induced Fc-dependent conjugate formation and cytotoxicity among AML blasts in vitro. Combination treatment also led to reduction in tumor volume and resulted in increased overall survival in murine engraftment models of AML. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol. 2018 Jul 24;30(8):375-383. | |||
